Skip to main content
. 2022 Dec 21;5(3):100592. doi: 10.1016/j.xkme.2022.100592

Table 2.

Biomarker Concentrations by Contrast-associated Acute Kidney Injury and Major Adverse Kidney Event.

Biomarker Preangiography
 Postangiography
Median (IQR)
 P Value P Valuel Median (IQR)
 P Value P Valuel
Event No Event Event No Event
CA-AKI
Urinary [TIMP-2]•[IGFBP7], (ng/mL)2/1000a,b 0.10 (0.05-0.20) 0.20 (0.05-0.40) 0.02 0.002 0.05 (0.05-0.06) 0.05 (0.05-0.10) 0.09 0.39
Urine creatinine-indexed urinary [TIMP-2]•[IGFBP7], (ng/mL)2/1,000 mg/dLc,d,e 0.0011 (0.0008-0.0024) 0.018 (0.001-0.0031) 0.009 0.86 0.0012 (0.0008-0.0015) 0.0013 (0.0009-0.002) 0.15 0.44
Plasma BNP, pg/mLf,g 87.0 (40.0-220.0) 74.30 (29.0-185.0) 0.35 0.91 91.50 (48.0-198.0) 83.0 (33.0-198.0) 0.42 0.81
Serum troponin, ng/mLh,i 0.02 (0.005-0.05) 0.02 (0.005-0.04) 0.18 0.25 0.02 (0.005-0.05) 0.02 (0.005-0.05) 0.54 0.10
Plasma hs-CRP, mg/Lj,k 4.60 (1.40-10.40) 3.50 (1.60-8.20) 0.41 0.65 4.80 (1.90-10.40) 3.30 (1.40-7.40) 0.08 0.06
Major adverse kidney events
Urinary [TIMP-2]•[IGFBP7], (ng/mL)2/1,000a,b 0.20 (0.10-0.35) 0.16 (0.05-0.30) 0.12 0.48 0.05 (0.05-0.20) 0.05 (0.05-0.10) 0.06 0.41
Urine creatinine-indexed urinary [TIMP-2]•[IGFBP7], (ng/mL)2/1,000 mg/dLc,d,e 0.002 (0.001-0.004) 0.002 (0.001-0.003) 0.06 0.06 0.002 (0.001-0.003) 0.001 (0.001-0.002) 0.008 0.76
Plasma BNP, pg/mLf,g 200.0 (60.0-349.0) 71.5 (29.0-172.0) <0.001 0.05 165.0 (63.0-386.0) 81.0 (33.0-189.0) <0.001 0.02
Serum troponin, ng/mLh,i 0.03 (0.02-0.13) 0.01 (0.005-0.04) <0.001 <0.001 0.04 (0.02-0.13) 0.02 (0.005-0.05) <0.001 0.01
Plasma hs-CRP, mg/Lj,k 9.55 (3.70-10.40) 3.40 (1.50-7.90) 0.001 0.01 9.90 (3.50-10.40) 3.20 (1.40-7.30) <0.001 0.002

Abbreviations: IQR, interquartile range; CA-AKI, contrast-associated acute kidney injury; TIMP, tissue inhibitor of matrix metalloproteinase; IGFBP, insulin growth factor binding protein; BNP, β natriuretic peptide; hs-CRP, high-sensitivity C-reactive protein; ng, nanograms; mL, milliliter; pg, picograms; L, liter; dL, deciliter

a

Preangiography urinary [TIMP-2]•[IGFBP7] concentrations were assayed in 797 patients

b

Postangiography urinary [TIMP-2]•[IGFBP7] concentrations were assayed in 842 patients

c

Preangiography urine creatinine-indexed urinary [TIMP-2]•[IGFBP7] concentrations were assayed in 791 patients

d

Postangiography urine creatinine-indexed urinary [TIMP-2]•[IGFBP7] concentrations were assayed in 836 patients

e

Normalized for urine creatinine

f

Preangiograph y plasma BNP concentrations were assayed in 884 patients

g

Postangiography plasma BNP concentrations were assayed in 838 patients

h

Preangiography serum troponin concentrations were assayed in 911 patients

I

Postangiography serum troponin concentrations were assayed in 846 patients

j

Preangiography plasma hs-CRP concentrations were assayed in 646 patients

k

Postangiography plasma hs-CRP concentrations were assayed in 592 patients

l

P values are from a multivariable model that included baseline eGFR and urinary albumin-creatinine ratio as covariates.